Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chester Lin"'
Autor:
Bilal Tariq, Ying C. Ou, Jennifer C. Stern, Vaibhav Mundra, Nicole Wong Doo, Patricia Walker, Katharine L. Lewis, Chester Lin, William Novotny, Srikumar Sahasranaman, Stephen Opat
Publikováno v:
Leukemialymphoma.
BTK inhibitor exposure increases significantly when coadministered with CYP3A inhibitors, which may lead to dose-related toxicities. This study explored the pharmacokinetics, efficacy, and safety of zanubrutinib when coadministered with moderate or s
Autor:
Tsung-Ying Yang, Chun-Chi Wu, Tsung-Chieh Chester Lin, Kun-Chieh Chen, Shih Lan Hsu, Chieh-Lin Jerry Teng
Publikováno v:
International Journal of Cancer. 142:92-108
In this study, we firstly showed that p53 transcriptionally represses Aurora-A gene expression through directly binding to its promoter. DNA affinity precipitation assay and chromatin immunoprecipitation assay indicated that p53 physically bound to t
Autor:
Lewis C. Strauss, D. Pezet, G. Deplanque, T.R.J. Evans, Edwin P. Rock, Alexander S. Rosemurgy, G. Bodoky, Chester Lin, M. Harrison, Bohuslav Melichar, A. Elekes, Igor Bazin, Peter O'Dwyer, Malcolm J. Moore, E. Van Cutsem
Publikováno v:
Annals of Oncology
Annals of Oncology, Oxford University Press (OUP), 2017, ⟨10.1093/annonc/mdw607⟩
Annals of Oncology, Elsevier, 2017, ⟨10.1093/annonc/mdw607⟩
Annals of Oncology, Oxford University Press (OUP), 2017, ⟨10.1093/annonc/mdw607⟩
Annals of Oncology, Elsevier, 2017, ⟨10.1093/annonc/mdw607⟩
Background Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate with limited treatment options. Gemcitabine provides a marginal survival benefit for patients with advanced PDAC. Dasatinib is a competitive inhibitor of Src kinase, which i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::499f81eede21d40b4da2581fa9588b48
https://hal.uca.fr/hal-01682149
https://hal.uca.fr/hal-01682149
Autor:
Amita Patnaik, Kyriakos P. Papadopoulos, Naoto Ohi, Edwin P. Rock, Geoffrey I. Shapiro, Jordan Berlin, Andrea J. Bullock, Keith T. Flaherty, Thomas E. Witzig, Gregory M. Cote, Chester Lin, Lon Smith, Anthony W. Tolcher, Dusan Kostic, Agnes Elekes, Drew W. Rasco, Thomas M. Habermann
Publikováno v:
The Oncologist
Lessons Learned OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study of OPB-111077 in unselected advanced cancers
Autor:
Jong Seok Lee, Santiago Viteri Ramirez, Chester Lin, Ji-Youn Han, Harold N. Keer, Hye Ryun Kim, Antoinette J. Wozniak, In-Jae Oh, D. Ross Camidge, Mohammad Azab, Benjamin Besse, Dae Ho Lee, Joan H. Schiller, Myung-Ju Ahn, Nathan A. Pennell, Erin M. Bertino
Publikováno v:
Journal of Clinical Oncology. 34:9059-9059
9059Background: Crizotinib (C) was the first approved ALK inhibitor for use in in ALK positive (pos) NSCLC, but resistance ultimately develops through both ALK-related and other signaling pathways....
Autor:
Thomas M. Habermann, Manish Monga, Naoto Ohi, Gregory M. Cote, Keith T. Flaherty, Amita Patnaik, Kyriakos P. Papadopoulos, Lon Smith, Andrea J. Bullock, Lin-Feng Tsai, Chester Lin, Jordan Berlin, Agnes Elekes, Anthony W. Tolcher, Thomas E. Witzig, Kunihiko Tatsumi, Geoffrey I. Shapiro, Drew Rascoe
Publikováno v:
Molecular Cancer Therapeutics. 14:B118-B118
Background: OPB-111077 is a new chemical entity with anticancer activity in vitro and in human tumor xenograft models. The compound modulates STAT3 phosphorylation but has no marked effect on activity of any of 69 tested human tyrosine or serine/thre